Boston Scientific EMPOWER Modular Pacing System — the FDA-approved (February 2022) modular leadless pacing system designed to integrate with Boston Scientific's existing cardiac rhythm management ecosystem — creates the three-way competitive market alongside Medtronic Micra and Abbott AVEIR, with the Leadless Pacemaker Market reflecting competitive market maturation as all three major CRM companies now offering leadless solutions.

EMPOWER modular concept — the design philosophy enabling EMPOWER to function as standalone single-chamber leadless pacemaker and as part of an integrated system combining leadless ventricular pacing with Boston Scientific's subcutaneous ICD (EMBLEM S-ICD) to create a lead-free ICD system — represents a unique commercial positioning. The MODULAR ATP trial demonstrating EMPOWER's safe integration with S-ICD creating the "LBBP alternative" for patients needing both pacing and defibrillation without transvenous leads.

Extravascular ICD plus leadless pacemaker — the combination of Boston Scientific's extravascular ICD (EV-ICD, Empower) with EMPOWER modular leadless creating a completely lead-free implantable device system for patients requiring both defibrillation and pacing — represents the most ambitious commercial positioning in the leadless market. The addressable patient population for lead-free ICD plus pacing potentially representing hundreds of thousands of patients annually.

Boston Scientific CRM ecosystem integration — the EMPOWER's integration with the LATITUDE remote monitoring platform, PG-ID identifier, and existing Boston Scientific EP workflow — creates the commercial advantage of fitting into established hospital relationships and workflow without requiring new remote monitoring infrastructure.

Do you think the lead-free ICD plus leadless pacemaker combination (EMPOWER plus S-ICD or EV-ICD) represents a clinically compelling alternative to conventional transvenous ICD, and what patient populations would benefit most?

FAQ

What is the Boston Scientific EMPOWER pacing system? EMPOWER Modular Pacing System (Boston Scientific): FDA approved February 2022; single-chamber RV leadless pacemaker; unique features: modular design enabling integration with S-ICD (subcutaneous ICD) or EV-ICD (extravascular ICD); anti-tachycardia pacing (ATP) capability for VT termination when used with compatible ICD; MODULAR ATP IDE trial: demonstrated safe ATP delivery from EMPOWER when integrated with S-ICD; market positioning: targeting patients needing both pacing and shock therapy without transvenous leads; single-chamber VR pacing capability; active fixation helix.

What is a lead-free ICD system and what patient populations benefit? Lead-free ICD concept: subcutaneous ICD (S-ICD, Boston Scientific) or extravascular ICD detecting/shocking VF without transvenous lead; combined with EMPOWER leadless pacemaker for patients also needing bradycardia support; advantages: completely eliminates transvenous leads and their complications; benefits: young patients avoiding decades of lead complications; venous access difficulties; prior lead infection; indications: patients with primary prevention ICD indication plus bradycardia requiring pacing; challenge: S-ICD cannot provide anti-tachycardia pacing or resynchronization pacing; EMPOWER ATP integration partially addresses pacing gap; growing market as lead-free concept matures.

#LeadlessPacemaker #EMPOWER #BostonScientificPacing #LeadFreeICD #SICD #CardiacCRM